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Background:  Data from DOSE-AHF suggests continuous infusion loop diuretics may not be superior to bolus dosing with regards to diuresis and 
clinical endpoints in patients with acute HF. Whether continuous infusions are more effective in patients on higher outpatient diuretic doses, who 
may be more diuretic refractory, is unclear.
Methods:  308 patients with acute HF receiving 80 to 240 mg oral furosemide equivalents were randomized in 2x2 design to (1) low (1x oral 
dose) vs. high intensity (2.5x oral) diuretics; (2) continuous vs. Q12 hour bolus dosing. Patients were grouped by outpatient dose (low: <120 mg 
furosemide, n=131; high: ≥120 mg; n=177). Characteristics between groups were compared using Wilcoxon rank-sum or Chi-square tests. Linear 
regression, with interaction between strategy (continuous vs. bolus) and outpatient dose, was used to assess associations between strategy and 
outcome.
Results:  As compared to the lower dose group, patients on a higher outpatient diuretic dose were less often on RAS inhibitors (p=.014), had worse 
renal function (p=.003) and more severe symptoms (by global and dyspnea VAS, p<.05 for each), but were similar in age, gender, HF etiology, LVEF, 
and blood pressure. Outpatient dose (or its interaction with bolus vs. continuous therapy) was not associated with changes in weight at 48 hr, or 
creatinine, global VAS or NT-proBNP at 72 hr. Patients on ≥120 mg outpatient furosemide had larger net fluid loss at 72 hr (NFL72) with bolus vs. 
continuous strategy (4436 vs. 4113 ml), whereas patients on <120 mg had larger NFL72 with continuous strategy (3877 vs. 4404 ml). Interaction 
between strategy and admission diuretic dose predicted NFL72 (p=.02). Patients admitted on <120 mg furosemide had shorter hospital length of 
stay compared to ≥120 mg (HR=0.77, 95% CI 0.61-0.97; p=.03).
Conclusions:  Higher outpatient diuretic dose on HF admission is associated with greater disease severity and longer length of stay. In patients 
admitted with acute HF, outpatient diuretic dose may impact the efficacy and therefore choice of initial diuretic strategy.
